Not available
Quote | Leap Therapeutics Inc. (NASDAQ:LPTX)
Last: | $2 |
---|---|
Change Percent: | -2.73% |
Open: | $1.88 |
Close: | $2 |
High: | $2.01 |
Low: | $1.8001 |
Volume: | 136,335 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Leap Therapeutics Inc. (NASDAQ:LPTX)
2024-05-13 10:58:13 ET Summary LPTX is developing DKN-01, a drug with potential in multiple types of cancer, including colorectal, esophagogastric, and endometrial cancer. LPTX's DisTinGuish study looks at DKN-01 in gastric cancer and gastroesophageal cancer patients. Part C of th...
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Message Board Posts | Leap Therapeutics Inc. (NASDAQ:LPTX)
Subject | By | Source | When |
---|---|---|---|
No one in their right mind gives 2 | VivaLasVegas | investorshub | 05/27/2022 4:28:22 AM |
LPTX Piper ups Leap Therapeutics target to $6 | stockguard | investorshub | 01/24/2022 12:19:32 AM |
AviseAnalytics: 4 SMALL-CAP BIOTECH STOCKS FOR YOUR INVESTMENT PORTFOLIO! $LPTX $VYGR $OCUL $MNMD | AviseAnalytics | investorshangout | 11/01/2021 12:06:18 PM |
yep, something big happening here. | Deano361 | investorshub | 09/30/2021 7:24:17 PM |
4.08 > hod. | crudeoil24 | investorshub | 09/30/2021 6:33:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...